It’s only fair to share… Lunresertib CAS 2719793-90-3 MF C18H20N4O2 MW 324.4 g/mol (1P)-2-amino-1-(3-hydroxy-2,6-dimethylphenyl)-5,6-dimethyl1H-pyrrolo[2,3-b]pyridine-3-carboxamideserine/ threonine kinase inhibitor, antineoplastic, N95U3A7N57, RP-6306, RP 6306 2-Amino-1-(3-hydroxy-2,6-dimethylphenyl)-5,6-dimethylpyrrolo[2,3-b]pyridine-3-carboxamide Lunresertib is an investigational new drug that is being evaluated for the treatment of cancer. It is an oral small molecule inhibitor of PKMYT1, developed by Repare Therapeutics.[1] This drug targets cell cycle regulation in tumors with specific …